Policy Statement

I. Analysis of the optic nerve and retinal nerve fiber layer in the diagnosis and evaluation of individuals with glaucoma or glaucoma suspects may be considered medically necessary when using any of the following techniques:
   A. Optical coherence tomography (OCT)
   B. Scanning laser ophthalmoscopy
   C. Scanning laser polarimetry (SLP)

II. The measurement of ocular blood flow, pulsatile ocular blood flow, or blood flow velocity is considered investigational in the diagnosis and follow-up of individuals with glaucoma.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

This policy addresses techniques used to evaluate glaucoma and does not address other ophthalmic conditions.

Coding

There is a CPT code for scanning computerized imaging of the optic nerve in the posterior segment:

- 92133: Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve

The following category III CPT code is for measurement of ocular blood flow by repetitive ocular blood flow measurement:

- 0198T: Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report

Description

Several techniques have been developed to measure the thickness of the optic nerve and retinal nerve fiber layer as a method to diagnose glaucoma. Measurement of ocular blood flow is also being evaluated as a diagnostic tool for glaucoma.

Related Policies

- Optical Coherence Tomography of the Anterior Eye Segment

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

**Regulatory Status**

A number of confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography devices have been cleared by the U.S. Food and Drug Administration (FDA) through the 510(k) process for imaging the posterior eye segment. For example, the RTVue XR optical coherence tomography Avanti™ (Optovue) is an optical coherence tomography system indicated for the in vivo imaging and measurement of the retina, retinal nerve fiber layer, and optic disc as a tool and aid in the clinical diagnosis and management of retinal diseases. The RTVue XR optical coherence tomography Avanti™ with Normative Database is a quantitative tool for comparing retina, retinal nerve fiber layer, and optic disk measurements in the human eye with a database of known normal subjects. It is intended as a diagnostic device to aid in the detection and management of ocular diseases. In 2016, the RTVue XR optical coherence tomography and Avanti™ with AngioVue™ Software was cleared by the FDA through the 510(k) process (K153080) as an aid in the visualization of vascular structures of the retina and choroid.

FDA product code: HLI, OBO.

In 2012, the iExaminer™ (Welch Allyn) was cleared for marketing by the FDA through the 510(k) process. The iExaminer™ consists of a hardware adapter and associated software (iPhone® App) to capture, store, send, and retrieve images from the PanOptic™ Ophthalmoscope (Welch Allyn) using an iPhone.

FDA product code: HKI.

**Table 1. Selected Ocular Imaging Devices Cleared by the U.S. Food and Drug Administration**

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510.k No.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESCAN 700 CALLISTO eye</td>
<td>Carl Zeiss Meditec AG</td>
<td>1/11/2019</td>
<td>K180229</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Retina Workplace</td>
<td>Carl Zeiss Meditec Inc</td>
<td>10/24/2018</td>
<td>K182318</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA+OCT and variants with High Magnification Module</td>
<td>Heidelberg Engineering GmbH</td>
<td>10/18/2018</td>
<td>K182569</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA+OCT and variants with OCT Angiography Module</td>
<td>Heidelberg Engineering GmbH</td>
<td>9/13/2018</td>
<td>K181594</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA + OCT and variants</td>
<td>Heidelberg Engineering GmbH</td>
<td>8/30/2018</td>
<td>K173648</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Image Filing Software NAVIS-EX</td>
<td>Nidek Co. Ltd</td>
<td>7/19/2018</td>
<td>K181345</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Device</td>
<td>Manufacturer</td>
<td>Date Cleared</td>
<td>510.k No.</td>
<td>Indication</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>--------------</td>
<td>-----------</td>
<td>------------</td>
</tr>
<tr>
<td>Avanti</td>
<td>Optovue Inc.</td>
<td>6/8/2018</td>
<td>K180660</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>P200TE</td>
<td>Optos plc</td>
<td>2/28/2018</td>
<td>K173707</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>DRI OCT Triton</td>
<td>Topcon Corporation</td>
<td>1/19/2018</td>
<td>K173119</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>IMAGEnet 6 Ophthalmic Data System</td>
<td>Topcon Corporation</td>
<td>11/1/2017</td>
<td>K171370</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA + OCT and variants Spectralis FA+OCT Spectralis ICGA+OCT Spectralis OCT Blue Peak Spectralis OCT with Multicolor</td>
<td>Heidelberg Engineering GmbH</td>
<td>11/1/2017</td>
<td>K172649</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>PRIMUS</td>
<td>Carl Zeiss Suzhou Co. Ltd.</td>
<td>6/21/2017</td>
<td>K163195</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Retina Workplace</td>
<td>Carl Zeiss Meditec AG</td>
<td>6/21/2017</td>
<td>K170638</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>iVue</td>
<td>Optovue Inc.</td>
<td>6/9/2017</td>
<td>K163475</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>3D OCT-1 Maestro</td>
<td>Topcon Corporation</td>
<td>3/3/2017</td>
<td>K170164</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>EnFocus 2300 EnFocus 4400</td>
<td>Bioptigen Inc.</td>
<td>12/9/2016</td>
<td>K162783</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>PLEX Elite 9000 SS-OCT</td>
<td>CARL ZEISS MEDITEC INC.</td>
<td>10/26/2016</td>
<td>K161194</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>3D OCT-1 Maestro</td>
<td>Topcon Corporation</td>
<td>7/28/2016</td>
<td>K161509</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>LSFG-NAVI</td>
<td>Softcare Co. Ltd</td>
<td>5/12/2016</td>
<td>K153239</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>Spectralis HRA + OCT and variants (e.g.s below) Spectralis FA+OCT Spectralis ICGA+OCT Spectralis OCT Blue Peak Spectralis OCT with Multicolor</td>
<td>Heidelberg Engineering GmbH</td>
<td>5/6/2016</td>
<td>K152205</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
<tr>
<td>RTVue XR OCT Avanti with AngioVue Software</td>
<td>OPTOVUE INC.</td>
<td>2/11/2016</td>
<td>K153080</td>
<td>Imaging of optic nerve and retinal nerve fiber layer</td>
</tr>
</tbody>
</table>
## Rationale

### Background

#### Diagnosis and Management

A comprehensive ophthalmologic exam is required for the diagnosis of glaucoma, but no single test is adequate to establish diagnosis. A comprehensive ophthalmologic examination includes assessment of the optic nerve, evaluation of visual fields, and measurement of ocular pressure. The presence of characteristic changes in the optic nerve or abnormalities in visual field, together with increased intraocular pressure (IOP), is sufficient for a definitive diagnosis. However, some patients will show ophthalmologic evidence of glaucoma with normal IOPs. These cases of normal-tension glaucoma are considered to be a type of primary open-angle glaucoma. Angle-closure glaucoma is another type of glaucoma associated with an increase in IOP. The increased IOP in angle-closure glaucoma arises from a reduction in aqueous outflow from the eye due to a closed angle in the anterior chamber. Diagnosis of angle-closure glaucoma is detailed in Blue Shield of California Medical Policy: Optical Coherence Tomography of the Anterior Eye Segment.
Conventional management of patients with glaucoma principally involves drug therapy to control elevated IOPs, and serial evaluation of the optic nerve, to follow disease progression. Standard methods of evaluation include careful direct examination of the optic nerve using ophthalmoscopy or stereo photography or evaluation of visual fields. There is interest in developing more objective, reproducible techniques both to document optic nerve damage and to detect early changes in the optic nerve and retinal nerve fiber layer before the development of permanent visual field deficits. Specifically, evaluating changes in retinal nerve fiber layer thickness has been investigated as a technique to diagnose and monitor glaucoma. However, IOP reduction is not effective in decreasing disease progression in a significant number of patients, and in patients with normal-tension glaucoma, there is never an increase in IOP. It has been proposed that vascular dysregulation is a significant cause of damage to the retinal nerve fiber layer, and there is interest in measuring ocular blood flow as both a diagnostic and a management tool for glaucoma. Changes in blood flow to the retina and choroid may be particularly relevant for diagnosis and treatment of normal-tension glaucoma. A variety of techniques have been developed, as described below. (Note: This evidence review only addresses techniques related to the evaluation of the optic nerve, retinal nerve fiber layer, or blood flow to the retina and choroid in patients with glaucoma.)

Techniques to Evaluate the Optic Nerve and Retinal Nerve Fiber Layer

Confocal Scanning Laser Ophthalmoscopy
Confocal scanning laser ophthalmoscopy is an image acquisition technique intended to improve the quality of the eye examination compared with standard ophthalmologic examination. A laser is scanned across the retina along with a detector system. Only a single spot on the retina is illuminated at any time, resulting in a high-contrast image of great reproducibility that can be used to estimate retinal nerve fiber layer thickness. In addition, this technique does not require maximal mydriasis, which may be problematic in patients with glaucoma. The Heidelberg Retinal Tomograph is a commonly used technology.

Scanning Laser Polarimetry
The retinal nerve fiber layer is birefringent (i.e., biorefractive), meaning that it causes a change in the state of polarization of a laser beam as it passes. A 780-nm diode laser is used to illuminate the optic nerve. The polarization state of the light emerging from the eye is then evaluated and correlated with retinal nerve fiber layer thickness. Unlike confocal scanning laser ophthalmoscopy, scanning laser polarimetry can directly measure the thickness of the retinal nerve fiber layer. GDx is a common scanning laser polarimetry device. GDx contains a normative database and statistical software package that compares scan results with age-matched normal subjects of the same ethnic origin. The advantages of this system are that images can be obtained without pupil dilation and evaluation can be completed in 10 minutes. Current instruments have added enhanced and variable corneal compensation technology to account for corneal polarization.

Optical Coherence Tomography
Optical coherence tomography uses near-infrared light to provide direct cross-sectional measurement of the retinal nerve fiber layer. The principles employed are similar to those used in B-mode ultrasound except light, not sound, is used to produce the 2-dimensional images. The light source can be directed into the eye through a conventional slit-lamp biomicroscope and focused onto the retina through a typical 78-diopter lens. This system requires dilation of the patient’s pupil. Optical coherence tomography analysis software is being developed to include optic nerve head parameters with spectral domain optical coherence tomography, analysis of macular parameters, and hemodynamic parameters with Doppler optical coherence tomography and optical coherence tomography angiography.

Pulsatile Ocular Blood Flow
The pulsatile variation in ocular pressure results from the flow of blood into the eye during cardiac systole. Pulsatile ocular blood flow can thus be detected by the continuous monitoring of IOP. The detected pressure pulse can then be converted into a volume measurement using the known relation.
between ocular pressure and ocular volume. Pulsatile blood flow is primarily determined by the choroidal vessels, particularly relevant to patients with glaucoma because the optic nerve is supplied in large part by choroidal circulation.

**Techniques to Measure Ocular Blood Flow**

A number of techniques have been developed to assess ocular blood flow. They include laser speckle flowgraphy, color Doppler imaging, Doppler Fourier domain optical coherence tomography, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, and retinal functional imaging.

**Laser Speckle Flowgraphy**

Laser speckle is detected when a coherent light source such as laser light is dispersed from a diffusing surface such as retinal and choroidal vessels and the circulation of the optic nerve head. The varying patterns of light can be used to determine red blood cell velocity and retinal blood flow. However, due to differences in the tissue structure in different eyes, flux values cannot be used for comparisons between eyes. This limitation may be overcome by subtracting background choroidal blood flow results from the overall blood flow results in the region of interest.

**Color Doppler Imaging**

Color Doppler imaging has also been investigated as a technique to measure the blood flow velocity in the retinal and choroidal arteries. This technique delivers ultrasound in pulsed Doppler mode with a transducer set on closed eyelids. The examination takes 30 to 40 minutes and is most effective for the mean velocity of large ophthalmic vessels such as the ophthalmic artery, the central retinal artery, and the short posterior ciliary arteries. However, total blood flow cannot be determined with this technique, and imaging is highly dependent on probe placement.

**Doppler Fourier Domain Optical Coherence Tomography**

Doppler Fourier domain optical coherence tomography is a noncontact imaging technique that detects the intensity of the light scattered back from erythrocytes as they move in the vessels of the ocular tissue. This induces a frequency shift that represents the velocity of the blood in the ocular tissue.

**Laser Doppler Velocimetry**

Laser Doppler velocimetry compares the frequency of reflected laser light from a moving particle with stationary tissue.

**Confocal Scanning Laser Doppler Flowmetry**

Confocal scanning laser Doppler flowmetry combines laser Doppler flowmetry with confocal scanning laser tomography. Infrared laser light is used to scan the retina, and the frequency and amplitude of Doppler shifts are determined from the reflected light. Determinations of blood velocity and blood volume are used to compute the total blood flow and create a physical map of retinal flow values.

**Literature Review**

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.
Glaucnoma is characterized by degeneration of the optic nerve (optic disc). Elevated intraocular pressure (IOP) has long been thought to be the primary etiology, but the relation between IOP and optic nerve damage varies among patients, suggesting a multifactorial origin. For example, some patients with clearly elevated IOP will show no optic nerve damage, while others with marginal or no pressure elevation will show optic nerve damage. The association between glaucoma and other vascular disorders (e.g., diabetes, hypertension) suggests vascular factors may play a role in glaucoma. Specifically, it has been hypothesized that reductions in blood flow to the optic nerve may contribute to the visual field defects associated with glaucoma.

Imaging of the Optic Nerve and Retinal Nerve Fiber Layer
Clinical Context and Test Purpose
The purpose of optic nerve and retinal nerve fiber layer imaging in patients with or suspected to have glaucoma is to inform a decision about appropriate treatment.

The question addressed in this evidence review is: Do imaging techniques for the optic nerve and retinal nerve fiber layer improve the net health outcome in individuals with glaucoma or suspected glaucoma?

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population is patients with glaucoma or who are suspected to have glaucoma and are being evaluated for diagnosis and monitoring of glaucoma progression.

**Interventions**
The tests being considered for assessment of the optic nerve and retinal nerve fiber layer include confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography. These tests are considered add-ons to the standard clinical evaluation.

**Comparators**
There is no single criterion standard for the diagnosis of glaucoma. This diagnosis is made from a combination of visual field testing, IOP measurement, and optic nerve and retinal nerve fiber layer assessment by an ophthalmologist.

**Outcomes**
Relevant outcomes include the clarity of the images and how reliable the test is at evaluating the optic nerve and nerve fiber layer changes. Demonstration that the information can be used to improve patient outcomes is essential for determining the utility of an imaging technology. Although direct evidence on the impact of the imaging technology from controlled trials would be preferred, in most cases, a chain of evidence needs to be constructed to determine whether there is a tight linkage between the technology and improved health outcomes. The outcomes relevant to this evidence review are IOP, loss of vision, and changes in IOP-lowering medications used to treat glaucoma. For patients with manifest glaucoma, the relevant period of follow-up is the immediate diagnosis of glaucoma. For patients with suspected glaucoma, longer-term follow-up would be needed to detect changes in visual field or retinal nerve fiber layer. Clinical utility might be demonstrated by a change in the management and reduction in glaucoma progression across follow-up.
Study Selection Criteria
For the evaluation of clinical validity of optic nerve and retinal nerve fiber layer imaging, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard.
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Systematic Reviews
In 2012, the Agency for Healthcare Research and Quality published a comparative effectiveness review of screening for glaucoma. Included were randomized controlled trials (RCTs), quasi-RCTs, observational cohort and case-control studies, and case series with more than 100 participants. The interventions evaluated included ophthalmoscopy, fundus photography or computerized imaging (ie, optical coherence tomography, retinal tomography, scanning laser polarimetry), pachymetry (ie, corneal thickness measurement), perimetry, and tonometry. No evidence was identified that addressed whether an open-angle glaucoma screening program led to a reduction in IOP, less visual impairment, reduction in visual field loss or optic nerve damage, or improvement in patient-reported outcomes. No evidence was identified on harms of a screening program. Over 100 studies were identified on the diagnostic accuracy of screening tests. However, due to the lack of a definitive diagnostic reference standard and heterogeneity in study designs, synthesis of results could not be completed.

A Cochrane review (2015) assessed the diagnostic accuracy of optic nerve head and retinal nerve fiber layer imaging for glaucoma. Included were 103 case-control studies and 3 cohort studies (N=16,260 eyes) that evaluated the accuracy of recent commercial versions of optical coherence tomography (spectral domain), Heidelberg Retinal Tomograph III, or scanning laser polarimetry (with the variable corneal compensator or enhanced corneal compensation) for diagnosing glaucoma. The population was patients referred for suspected glaucoma, typically due to an elevated IOP, abnormal optic disc appearance, and/or an abnormal visual field identified in primary eye care. Population-based screening studies were excluded. Most comparisons examined different parameters within the 3 tests, and the parameters with the highest diagnostic odds ratio were compared. The 3 tests (optical coherence tomography, Heidelberg Retinal Tomograph III, scanning laser polarimetry) had similar diagnostic accuracy. Specificity was close to 95%, while sensitivity was 70%. Because a case-control design with healthy participants and glaucoma patients was used in nearly all studies, concerns were raised about the potential for bias, overestimation of accuracy, and applicability of the findings to clinical practice.

A systematic review, conducted by Chou et al (2022), was commissioned by the US Preventive Services Task Force (USPSTF) to update its recommendations on screening for glaucoma in adults. A total of 83 studies were included, of which 53 evaluated the diagnostic accuracy of screening tests (optical coherence tomography, optic disc photography, ophthalmoscopy and biomicroscopy, pachymetry, tonometry, and visual fields). Most studies evaluated spectral-domain optical coherence tomography (29 studies; n=11,434). Retinal nerve fiber layer thickness on spectral-domain optical coherence tomography was associated with a pooled sensitivity of 0.79 (95% confidence interval [CI], 0.75 to 0.83) and specificity of 0.92 (95% CI, 0.87 to 0.96) for distinguishing between glaucomatous eyes and controls, based on 15 studies; the pooled area under the receiver operating characteristic curve was 0.90 (95% CI, 0.86 to 0.93), based on 16 studies. Evidence on diagnostic accuracy was also robust for tonometry and the Humphrey Visual Field Analyzer but limited for other screening tests.
Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

A technology assessment, conducted by Lin et al (2007) for the American Academy of Ophthalmology (AAO), reviewed 159 studies, published between 2003 and 2006, evaluating optic nerve head and retinal nerve fiber layer devices used to diagnose or detect glaucoma progression. The assessment concluded: “The information obtained from imaging devices is useful in clinical practice when analyzed in conjunction with other relevant parameters that define glaucoma diagnosis and progression.” Management changes for patients diagnosed with glaucoma may include the use of IOP-lowering medications, monitoring for glaucoma progression, and potentially surgery to slow the progression of glaucoma.

Section Summary: Imaging of the Optic Nerve and Retinal Nerve Fiber Layer
Numerous studies and systematic reviews have described findings from patients with glaucoma using confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography. A recent systematic review found that retinal nerve fiber layer thickness on spectral-domain optical coherence tomography was associated with a pooled sensitivity of 0.79 and specificity of 0.92 for glaucoma diagnosis. Although the specificity in several studies was high, it is likely that accuracy was overestimated due to the case-control designs used in the studies. The literature and specialty society guidelines have indicated that optic nerve analysis using confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography are established add-on tests that can be used with other established tests to improve the diagnosis and direct management of patients with glaucoma and those who are glaucoma suspects. Management changes for patients diagnosed with glaucoma may include the use of IOP-lowering medications, monitoring for glaucoma progression, and potentially surgery.

Evaluation of Ocular Blood Flow
Clinical Context and Test Purpose
The diagnosis and monitoring of optic nerve damage are essential for evaluating the progression of glaucoma and determining appropriate treatment. Measurement of ocular blood flow has been studied as a technique to evaluate patients with glaucoma or suspected glaucoma. One potential application is the early detection of normal-tension glaucoma.

The purpose of evaluating ocular blood flow in patients who have glaucoma or suspected glaucoma is to inform a decision about appropriate treatment.

The question addressed in this evidence review is: Does evaluation of ocular blood flow using various techniques (e.g., color Doppler imaging, Doppler Fourier domain optical coherence tomography, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, retinal functional imager) in patients with glaucoma or suspected glaucoma improve diagnosis and monitoring of glaucoma? The following PICO was used to select literature to inform this review.

Populations
The relevant population is patients with glaucoma or suspected glaucoma who are being evaluated for diagnosis and monitoring of glaucoma progression. Tests for assessment of the ocular blood flow may have particular utility for normal-tension glaucoma.
Interventions
The tests being considered for assessment of the ocular blood flow include color doppler imaging, Doppler Fourier domain optical coherence tomography, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, and retinal functional imager.

Many of these procedures are performed with specialized equipment. While reports of use are longstanding (e.g., Bafa et al [2001]7,), investigators have commented on the complexity of these parameters8, and have noted that many of these technologies are not commonly used in clinical settings.9.

Comparators
There is no criterion standard for the diagnosis of glaucoma. The diagnosis of glaucoma is made using a combination of visual field testing, IOP measurements, and optic nerve and retinal nerve fiber layer assessment.

Outcomes
Relevant outcomes include the reliability of the test for evaluating ocular blood flow and the association between ocular blood flow parameters and glaucoma progression. Demonstration that the information can be used to improve patient outcomes is essential to determining the utility of a diagnostic technology. Although direct evidence on the impact of the imaging technology from controlled trials would be preferred, in most cases, a chain of evidence is needed to determine whether there is a tight linkage between the technology and improved health outcomes. The outcomes relevant to this evidence review are IOP, loss of vision, and changes in IOP-lowering medications used to treat glaucoma.

For patients with manifest glaucoma, the relevant period of follow-up is the immediate diagnosis of glaucoma. For patients with suspected glaucoma, longer-term follow-up would be needed to detect changes in IOP and loss of vision. Clinical utility might be demonstrated by a change in the management and reduction in glaucoma progression across follow-up.

Study Selection Criteria
For the evaluation of clinical validity of tests for assessment of ocular blood flow, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard.
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
A technology assessment, conducted by WuDunn et al (2021) for the AAO, reviewed 75 articles published through June 2020, evaluating the utility of optical coherence tomography angiography of the peripapillary or macular regions to help detect glaucomatous damage associated with the diagnosis of primary open-angle glaucoma.10 Per the AAO, the majority of data demonstrates that peripapillary microcirculation measured by vessel density on optical coherence tomography angiography is decreased in glaucomatous versus healthy eyes. Therefore, this technology can be helpful in detecting vessel density loss associated with glaucoma. Furthermore, peripapillary, macular, and choroidal vessel density parameters may complement visual field and structural optical coherence tomography measurements in the diagnosis of glaucoma.
Systematic Review

Gu et al (2021) published a systematic review with meta-analysis evaluating the diagnostic value of laser speckle flowgraphy in glaucoma by investigating the mean blur rate in the optic nerve head. A total of 15 studies, including 692 glaucomatous and 386 healthy eyes, were included; only 1 study was based in the US (Tables 2 and 3). Results are summarized in Table 4. Briefly, the mean blur rate was significantly reduced in glaucomatous versus healthy eyes in the entire area, indicating that blood flow velocity in all areas of the optic nerve head was lower in glaucomatous eyes. Furthermore, the mean blur rate was significantly reduced in glaucomatous versus healthy eyes in the tissue area, indicating that there is insufficient blood supply in the deep fundus tissues and optic nerve head ischemia in glaucomatous eyes. Lastly, the mean blur rate was significantly reduced in glaucomatous versus healthy eyes in the vascular area, indicating that patients with glaucoma have an insufficient retinal blood supply. The authors concluded that while laser speckle flowgraphy is a feasible diagnostic tool for glaucoma, more prospective studies are needed to fully evaluate this technology.

Table 2. Comparison of Trials/Studies Included in Systematic Review & Meta-Analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Gu et al (2021)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aizawa (2011)</td>
<td>●</td>
</tr>
<tr>
<td>Gardiner (2019)</td>
<td>●</td>
</tr>
<tr>
<td>Iida (2017)</td>
<td>●</td>
</tr>
<tr>
<td>InoueYanagimachi (2018)</td>
<td>●</td>
</tr>
<tr>
<td>Kiyota (2017)</td>
<td>●</td>
</tr>
<tr>
<td>Kiyota (2017)</td>
<td>●</td>
</tr>
<tr>
<td>Kiyota (2018)</td>
<td>●</td>
</tr>
<tr>
<td>Kobayashi (2014)</td>
<td>●</td>
</tr>
<tr>
<td>Kohmoto (2019)</td>
<td>●</td>
</tr>
<tr>
<td>Kuroda (2020)</td>
<td>●</td>
</tr>
<tr>
<td>Mursch-Edlmayr (2018)</td>
<td>●</td>
</tr>
<tr>
<td>Mursch-Edlmayr (2019)</td>
<td>●</td>
</tr>
<tr>
<td>Mursch-Edlmayr (2020)</td>
<td>●</td>
</tr>
<tr>
<td>Shiga (2016)</td>
<td>●</td>
</tr>
<tr>
<td>Takeyama (2018)</td>
<td>●</td>
</tr>
</tbody>
</table>

Table 3. Systematic Review & Meta-Analysis Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gu et al (2021)</td>
<td>Through Dec 2020</td>
<td>15</td>
<td>Patients with glaucomatous or healthy eyes undergoing laser speckle flowgraphy to examine the ocular blood flow. The majority of participants in the included studies were Japanese (N=11 studies).</td>
<td>692 glaucomatous eyes; 386 healthy eyes.</td>
<td>Observational studies or randomized controlled trials.</td>
<td>N/A</td>
</tr>
</tbody>
</table>

N/A: not applicable.

Table 4. Systematic Review & Meta-Analysis Results

<table>
<thead>
<tr>
<th>Study</th>
<th>MBR – entire area</th>
<th>MBR – tissue area</th>
<th>MBR – vascular area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gu et al (2021)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total N</td>
<td>541</td>
<td>660</td>
<td>573</td>
</tr>
<tr>
<td>Glaucomatous eyes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy eyes</td>
<td>254</td>
<td>372</td>
<td>268</td>
</tr>
<tr>
<td>MD (95% CI)</td>
<td>-5.59 (-6.19 to -4.99)</td>
<td>-2.2 (-2.49 to -1.91)</td>
<td>-5.92 (-7.77 to -4.07)</td>
</tr>
<tr>
<td>p-value</td>
<td>.1</td>
<td>.07</td>
<td>.0003</td>
</tr>
</tbody>
</table>

CI: confidence interval; MBR: mean blur rate; MD: mean difference
Nonrandomized Studies
Abegao Pinto et al (2016) reported on the results from the prospective, cross-sectional, case-control, Leuven Eye Study, which included 614 individuals who had primary open-angle glaucoma (n=214), normal-tension glaucoma (n=192), ocular hypertension (n=27), suspected glaucoma (n=41), or healthy controls (n=140). The study objective was to identify the blood flow parameters most highly associated with glaucoma using technology commonly available in an ophthalmologist’s office or hospital radiology department. Assessment of ocular blood flow included color doppler imaging, retinal oximetry, dynamic contour tonometry, and optical coherence tomography enhanced-depth imaging of the choroid. The glaucoma groups had higher perfusion pressure than controls (p<.001), with lower velocities in both central retinal vessels (p<.05), and choroidal thickness asymmetries. The normal-tension glaucoma group, but not the primary open-angle glaucoma group, had higher retinal venous saturation than healthy controls (p=.005). There were no significant differences in macular scans. The diagnostic accuracy and clinical utility were not addressed.

Kurusheva et al (2017) compared ocular blood flow with choroidal thickness to determine which had a higher diagnostic value for detecting early glaucoma. Thirty-two patients with pre-perimetric glaucoma were matched with 30 control patients. Using optical coherence tomography, retinal nerve fiber layer thickness between groups was found to be comparable; the ganglion cell complex was thicker in the control patients, and there was no significant difference between groups for choroidal foveal loss volume. Mean blood flow velocity in the vortex veins had the highest area under receiver operating characteristic curve (1.0) and z-value (5.35). Diastolic blood flow velocity in the central retinal artery had a diagnostic value of 2.74 and area under receiver operating characteristic curve of 0.73. The authors concluded that this study suggested a diagnostic benefit in measuring blood flow velocities.

Witkowska et al (2017) investigated blood flow regulation using laser speckle flowgraphy in 27 individuals. In this prospective study, the authors specifically looked at mean blur rate blood flow in the optic nerve head and a peripapillary region. First, participants’ blood flow was measured when they were in a sitting position; then, participants were asked to perform an isometric “squatting” exercise for 6 minutes. Compared with baseline (sitting), exercise significantly increased ocular perfusion blood pressure (78.5%), mean blur rate in the tissue of the optic nerve head (18.1%), and mean blur rate in the peripapillary region (21.1±8.3%) (p<.001). Few studies have used laser speckle flowgraphy to study autoregulation of ocular blood flow during a change in blood pressure, and this study is limited to Japanese populations. Despite the lack of literature and limited population, the authors noted laser speckle flowgraphy could be a valuable tool to study the regulation of blood flow in the optic nerve head, particularly in patients suspected of having glaucoma or patients who have glaucoma.

Rusia et al (2011) reported on use of color doppler imaging in normal and glaucomatous eyes. Using data from other studies, a weighted mean was derived for the peak systolic velocity, end-diastolic velocity, and Pourcelot Resistive Index in the ophthalmic, central retinal, and posterior ciliary arteries. Data from 3061 glaucoma patients and 1072 controls were included. Mean values for glaucomatous eyes were within 1 standard deviation of the values for controls for most color doppler imaging parameters. Methodologic differences created interstudy variance in color doppler imaging values, complicating the construction of a normative database and limiting its utility. The authors noted that because the mean values for glaucomatous and normal eyes had overlapping ranges, caution should be used when classifying glaucoma status based on a single color doppler imaging measurement. Tables 5 and 6 summarize characteristics and results of key nonrandomized studies, respectively. Tables 7 and 8 summarize study limitations.

Table 5. Summary of Key Nonrandomized Study Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>Country</th>
<th>Dates</th>
<th>Participants</th>
<th>Treatment 1</th>
<th>Treatment 2</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kuryshova et al (2017)</td>
<td>Prospective</td>
<td>Russia</td>
<td>NR</td>
<td>Patients with pre-perimetric glaucoma (n=32)</td>
<td>Optical coherence tomography</td>
<td>N/A</td>
<td>NR</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
Ophthalmologic Techniques That Evaluate the Posterior Segment for Glaucoma

Study | Study Type | Country | Dates | Participants | Treatment 1 | Treatment 2 | Follow-Up
--- | --- | --- | --- | --- | --- | --- | ---
Witkowska et al (2017) | Prospective | Austria | 2015-2016 | Healthy participants (N=27). All participants were White. | Laser speckle flowgraphy | N/A | 6 minutes

N/A: not applicable; NR: not reported.

Table 6. Summary of Key Nonrandomized Study Results

<table>
<thead>
<tr>
<th>Study</th>
<th>AUC and Diagnostic Value</th>
<th>Increase in OPP from Baseline</th>
<th>Increase in MTONH from Baseline</th>
<th>Increase in MTPPR from Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurysheva et al (2017)</td>
<td>AUC; p-value</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>MBFV in VV</td>
<td>1.0; &lt;.0001</td>
<td>78.5+/−19.8%</td>
<td>18.1+/−7.7%</td>
<td>211+/−8.3%</td>
</tr>
<tr>
<td>MBFV in CRV</td>
<td>0.85; .0001</td>
<td>\</td>
<td>\</td>
<td>\</td>
</tr>
<tr>
<td>DBFV in CRA</td>
<td>0.73; .006</td>
<td>\</td>
<td>\</td>
<td>\</td>
</tr>
<tr>
<td>DBFV in LSPCA</td>
<td>0.71; .011</td>
<td>\</td>
<td>\</td>
<td>\</td>
</tr>
<tr>
<td>Witkowska et al (2017)</td>
<td>\</td>
<td>\</td>
<td>\</td>
<td>\</td>
</tr>
</tbody>
</table>

AUC: area under the receiver operating characteristic curve; CRA: central retinal artery; CRV: central retinal vein; DBFV: diastolic blood flow velocity; LSPCA: lateral short posterior ciliary artery; MBFV: mean blood flow velocity; MTPPR: mean blur rate in the peripapillary region; MTONH: mean blur rate in the tissue of the optic nerve head; NR: not reported; OPP: ocular perfusion pressure; VV: vortex veins.

Table 7. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurysheva et al (2017)</td>
<td>3. Study population included healthy controls; 4. Enrolled populations do not reflect relevant diversity</td>
<td>3. Intervention applied to all patients; No test utilized as comparator</td>
<td>5. Adverse events of test not described</td>
<td>1. Follow-up not reported</td>
<td></td>
</tr>
<tr>
<td>Witkowska et al (2017)</td>
<td>3. Study population was healthy individuals; 4. Enrolled populations do not reflect relevant diversity</td>
<td>3. No test utilized as comparator</td>
<td>5. Adverse events of test not described</td>
<td>1. Follow-up evaluated short-term changes only</td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.
- Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
- Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
- Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).
- Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).
Table 8. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Selection*</th>
<th>Blindingb</th>
<th>Delivery of Testc</th>
<th>Selective Reportingd</th>
<th>Data Completenesse</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kuryshova et al (2017)28,</td>
<td>1. Selection of patients not described; 2. Selection of control subjects was not randomized, but based on person accompanying patients</td>
<td>1. Examiner not blinded to patient group</td>
<td>4. Evaluator description not provided</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Witkowska et al (2017)29,</td>
<td>1. Selection of patients not described</td>
<td>1. All patients were healthy and underwent same treatment, therefore no blinding was utilized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

* Selection key: 1. Selection not described; 2. Selection not random or consecutive (ie, convenience).
* Blinding key: 1. Not blinded to results of reference or other comparator tests.
* Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.
* Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.
* Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

The clinical utility of techniques to evaluate ocular blood flow is similar to that for other imaging techniques. The objective is to improve the diagnosis and direct management of patients with glaucoma or suspected glaucoma. Measures of ocular blood flow may have particular utility for the diagnosis and monitoring of normal-tension glaucoma.

The only longitudinal study identified is a study by Calvo et al (2012) on the predictive value of retrobulbar blood flow velocities in a prospective series of 262 patients who were glaucoma suspects.31 At baseline, all participants had normal visual field, increased IOP (mean, 23.56 mm Hg), and glaucomatous optic disc appearance. Blood flow velocities were measured by color doppler imaging during the baseline examination, and conversion to glaucoma was assessed at least yearly according to changes observed with confocal scanning laser ophthalmoscopy. During the 48-month follow-up, 36 (13.7%) patients developed glaucoma and 226 did not. Twenty (55.5%) of those who developed glaucoma also showed visual field worsening (moderate agreement, $\kappa=0.38$). Mean end-
diastolic and mean velocity in the ophthalmic artery were significantly reduced at baseline in subjects who developed glaucoma compared with subjects who did not.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The evidence does not permit any inferences about the utility of ocular blood flow evaluation in the evaluation of glaucoma.

Section Summary: Evaluation of Ocular Blood Flow
Techniques to measure ocular blood flow or ocular blood velocity are being evaluated for the diagnosis of glaucoma. Data for these techniques remain limited. Current literature focuses on which technologies are most reliably associated with glaucoma. Literature reviews have not identified studies that suggest whether these technologies improve the diagnosis of glaucoma or whether measuring ocular blood flow in patients with glaucoma or suspected glaucoma improves health outcomes.

Supplemental Information
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In 2009, clinical input was sought to help determine whether the use of optic nerve or retinal nerve fiber layer imaging or ocular blood flow evaluation for individuals with glaucoma or suspected glaucoma would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 4 respondents, including 1 physician specialty society and 3 academic medical centers. For individuals who have glaucoma or suspected glaucoma who receive imaging of the nerve and retinal nerve fiber layer, clinical input supports that this use provides a clinically meaningful improvement in net health outcome and indicates that this use is consistent with generally accepted medical practice. Most reviewers supported the use of confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography in the care of patients with glaucoma and those with suspected glaucoma. Reviewers provided data to demonstrate that this testing is equivalent to expert assessment of optic disc photography for both detecting glaucoma and showing disease progression. Reviewers also commented on favorable aspects of this testing. For example, unlike other glaucoma testing, these tests can be done more easily (e.g., testing does not always need to be done with dilated pupils) and ambient light level may be (is) less critical. In addition, while serial stereo photographs of the optic nerves are considered by many as the criterion standard, they are not always practical, especially for general ophthalmologists. This testing also requires less cooperation from the patient, which can help when evaluating some older patients.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.
American Academy of Ophthalmology
In 2020, the American Academy of Ophthalmology issued 2 preferred practice patterns on primary open-angle glaucoma suspect and primary open-angle glaucoma, both recommending evaluation of the optic nerve and retinal nerve fiber layer. The documents stated that stereoscopic visualization and computer-based imaging of the optic nerve head and retinal nerve fiber layer provide different information about the optic nerve and are complementary. Both imaging methods are useful adjuncts as part of a comprehensive clinical examination. The guidelines described 3 types of computer-based imaging devices (confocal scanning laser ophthalmoscopy, scanning laser polarimetry, optical coherence tomography) currently available for glaucoma, which are similar in their ability to distinguish glaucoma from controls and noted that "computer-based digital imaging of the optic nerve head and retinal nerve fiber layer is routinely used to provide quantitative information to supplement the clinical examination of the optic nerve.... computerized imaging may be useful to distinguish between glaucomatous and nonglaucomatous retinal nerve fiber layer thinning." In addition, the Academy concluded that, as device technology evolves, the performance of diagnostic imaging devices is expected to improve.

U.S. Preventive Services Task Force Recommendations
The U.S. Preventive Task Force (USPSTF) published recommendations on screening for primary open-angle glaucoma in adults (40 years or older) in 2022. Based on findings from the systematic review by Chou et al (discussed in Rationale section), the USPSTF concluded that the evidence is insufficient to assess the balance of benefits and harms of screening in these patients. This recommendation is consistent with the previous 2013 statement. With regard to screening tests, the USPSTF states: "Diagnosis of open-angle glaucoma is based on a combination of tests showing degenerative changes in the optic disc, increased IOP [intraocular pressure], and defects in visual fields... Imaging tests such as optical coherence tomography (OCT) or spectral-domain OCT (which analyzes the spectrum of reflected light on the retina) and optic disc photography (to view the optic nerve head, retina, or both) can supplement the clinical examination."

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 9.

Table 9. Summary of Key Trials
<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT05344274</td>
<td>Direct Measures of Retinal Blood Flow and Autoregulation as Robust Biomarkers for Early Glaucoma</td>
<td>90</td>
<td>Sep 2026 (recruiting)</td>
</tr>
<tr>
<td>NCT04646122</td>
<td>Predicting Glaucoma Progression with Optical Coherence Tomography Structural and Angiographic Parameters</td>
<td>100</td>
<td>Mar 2022 (recruitment status unknown)</td>
</tr>
<tr>
<td>NCT01957267</td>
<td>Longitudinal Observational Study Using Functional and Structural Optical Coherence Tomography to Diagnose and Guide Treatment of Glaucoma</td>
<td>160</td>
<td>Dec 2025 (recruiting)</td>
</tr>
<tr>
<td>NCT02178085</td>
<td>Ocular Blood Flow Assessment in Glaucoma (OBAMAg)</td>
<td>62</td>
<td>Sep 2019 (recruitment status unknown)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
References


**Documentation for Clinical Review**

**Please provide the following documentation:**

- History and physical and/or consultation notes including:
- Clinical indications/justification of procedure
Ophthalmologic Techniques That Evaluate the Posterior Segment for Glaucoma

- Comprehensive ophthalmologic examination
- Comorbidities, including vascular disorders
- Treatment plan
- Prior ophthalmic diagnostic imaging with interpretation and report results if done
- Prior optic nerve analysis outcomes if done

Post Service (in addition to the above, please include the following):
- Results/reports of tests performed

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>0198T</td>
<td>Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report</td>
</tr>
<tr>
<td></td>
<td>92133</td>
<td>Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>05/29/2015</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>10/01/2016</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2017</td>
<td>Policy title change from Ophthalmologic Techniques for Evaluating Glaucoma</td>
</tr>
<tr>
<td></td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2018</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2019</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2020</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
<tr>
<td>05/01/2021</td>
<td>Annual review. Policy statement and literature updated.</td>
</tr>
<tr>
<td>05/01/2022</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
<tr>
<td>05/01/2023</td>
<td>Annual review. Policy statement and literature review updated.</td>
</tr>
</tbody>
</table>

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to
treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.
## Policy Statement

Analysis of the optic nerve and retinal nerve fiber layer in the diagnosis and evaluation of patients with glaucoma or glaucoma suspects may be considered medically necessary when using any of the following techniques:

1. **Optical coherence tomography (OCT)**
2. **Scanning laser ophthalmoscopy**
3. **Scanning laser polarimetry (SLP)**

The measurement of ocular blood flow, pulsatile ocular blood flow, or blood flow velocity is considered investigational in the diagnosis and follow-up of patients with glaucoma.

### Before
- **Red font:** Verbiage removed

### After
- **Blue font:** Verbiage Changes/Additions

Ophthalmologic Techniques That Evaluate the Posterior Segment for Glaucoma 9.03.06

Policy Statement:
Analysis of the optic nerve and retinal nerve fiber layer in the diagnosis and evaluation of patients with glaucoma or glaucoma suspects may be considered medically necessary when using any of the following techniques:

1. Optical coherence tomography (OCT)
2. Scanning laser ophthalmoscopy
3. Scanning laser polarimetry (SLP)

The measurement of ocular blood flow, pulsatile ocular blood flow, or blood flow velocity is considered investigational in the diagnosis and follow-up of patients with glaucoma.

II. The measurement of ocular blood flow, pulsatile ocular blood flow, or blood flow velocity is considered investigational in the diagnosis and follow-up of individuals with glaucoma.